Signal #144412 · SEC 8-K

$PVLA SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $PVLA filing catalyst

Why did $PVLA trigger an AI stock catalyst alert?

$PVLA triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.5/10). Headline: Palvella Reports Q3 2026: FDA Grants Priority Review for QTORIN Rapamycin, PDUFA Feb 28 2027. Key points: - FDA accepted NDA and granted Priority Review for QTORIN Rapamycin with PDUFA date set for Feb 28, 2027. - Q3 net loss expanded to $24.6M ($1.70/share) from $11.3M ($1.03/share) in prior year due to scaling operations. - Cash, cash equivalents and short-term investments stood at $236.7M as of Sept 30, 2026.

How did $PVLA stock react after the SEC filing?

After the SEC 8-K for $PVLA, observed market reaction: T0 price $162.28. Past moves do not guarantee future results.

Where can I get real-time $PVLA SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $PVLA via Telegram and the VIP Web Terminal from €10/month.

$PVLA

$PVLA – Palvella Reports Q3 2026: FDA Grants Priority Review for QTORIN Rapamycin, PDUFA Feb 28 2027

PALVELLA THERAPEUTICS, INC.

2026-11-05 00:00:00 UTC · SEC 8-K · All $PVLA

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+6.5 / 10)

FDA accepted NDA and granted Priority Review for QTORIN Rapamycin with PDUFA date set for Feb 28, 2027.
Q3 net loss expanded to $24.6M ($1.70/share) from $11.3M ($1.03/share) in prior year due to scaling operations.
Cash, cash equivalents and short-term investments stood at $236.7M as of Sept 30, 2026.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →